All News

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.

In patients with residual disease after curative resection of colorectal cancer, Lonsurf showed a numerical improvement in DFS, though not significant.

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of cholangiocarcinoma.

When deciding if reoperation is an option in recurrent glioblastoma, factors like tumor location, therapy history and patient health should be considered.

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among patients with gliomas.

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events and reduced overall survival.

From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less invasive or complex surgeries.

Concomitant radiotherapy plus temozolomide significantly increased progression-free survival versus radiotherapy alone in IDH-wildtype glioblastoma.

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated metastatic colorectal cancer.

It took a nightmare about a second cancer to shake me out of my complacency, and I nearly called 9 1 1.

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer.

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor approved for first line therapy.

Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis diagnosis.

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear-cell renal cell carcinoma.

Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.

The recent American Cancer Society’s Cancer Statistics, 2025 report was released revealing a sobering trend for pancreatic cancer.

As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer.

Cancer rehab is a fairly new and growing specialty in the therapy world.

Breast cancer surgery is a deeply personal and often challenging experience for many women.

If you’re reading this, you recognize the importance of diet and nutrition after a cancer diagnosis.

Statistics show that breast cancer is most common in women over 50, but that doesn’t mean it can’t affect individuals outside that age range.